Why Illumina (ILMN) Stock Is Sinking Today
Illumina plunged 19.3% on Friday after third-quarter results that topped profit estimates and raised its 2026 forecast failed to ease worries about slowing growth.

65 stocks we cover, with a median revenue growth +7.8% and a median operating margin 13.3% over the last 12 months.
Illumina plunged 19.3% on Friday after third-quarter results that topped profit estimates and raised its 2026 forecast failed to ease worries about slowing growth.

Stryker's revenue rose 7.7% to $6.52 billion, short of the $6.58 billion expected, and it cut its 2026 growth forecast. The stock was down 7.6% Friday morning.

Bristol Myers Squibb's revenue rose 7% to $13.07 billion, beating the $12.56 billion Zacks consensus, and it raised its 2026 sales forecast. The stock rose 1.4% on Thursday.

Gilead's revenue rose 7% to $8.30 billion, beating the $7.81 billion expected, and it raised its 2026 sales forecast. The stock was up 3% after hours.

Merck's sales rose 5% to $18.09 billion, ahead of the $17.31 billion expected, and it raised its 2026 profit forecast. The stock rose 3.8% on Thursday.

AbbVie reports before the open on Friday. Analysts expect adjusted EPS of $3.74 to $3.79, within or above the $3.73 to $3.77 the company guided to after an 11-cent charge for acquired research.

Lilly's revenue rose 39% to $24.40 billion, beating the $22.61 billion expected, and it raised its 2026 sales forecast by $5.5 billion at the midpoint. The stock jumped 6.6% to a record close.

Moderna plunged 17.6% on Thursday after its melanoma data posted early, Lam Research plunged 11.8% on a supply warning, and Spotify soared 11.1% on its profit forecast.



By market value. Tap a column to sort.